Fetal consequences of maternal antiretroviral nucleoside reverse transcriptase inhibitor use in human and nonhuman primate pregnancy

Current Opinion in Pediatrics

Volumn 27, Issue 2, 2015, Pages 233-239

  Poirier, Miriam C ^a   Gibbons, Alexander T ^a   Rugeles, Maria T ^b   Andre Schmutz, Isabelle ^c   Blanche, Stephane ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^c INSERM   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

aneuploidy; electron microscopy; genotoxicity; mitochondrial DNA; zidovudine

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; MITOCHONDRIAL DNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANEUPLOIDY; BONE MARROW CELL; ERYTHROCEBUS PATAS; FETOTOXICITY; GENOTOXICITY; HEART LEFT VENTRICLE MUSCLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MITOCHONDRIAL TOXICITY; MORPHOLOGY; NONHUMAN; PREGNANCY; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRIMATE; PRIORITY JOURNAL; REVIEW; UMBILICAL CORD; VERTICAL TRANSMISSION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; FEMALE; FETOMATERNAL TRANSFUSION; HIV INFECTIONS; INFANT; NEWBORN; PHYSIOLOGY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL;

ANEUPLOIDY; ANIMALS; ANIMALS, NEWBORN; DISEASE MODELS, ANIMAL; DNA, MITOCHONDRIAL; ERYTHROCEBUS PATAS; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 84922268983     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0000000000000193     Document Type: Review

References (31)

1. Heidari S, Mofenson LM, Bekker LG. Realization of an aids-free generation: ensuring sustainable treatment for children. JAMA 2014; 312: 339-340.
2. Govender T, Coovadia H. Eliminating mother to child transmission of HIV-1 and keeping mothers alive: recent progress. J Infect 2014; 68 (Suppl 1): S57-62
3. Feeney ER, Mallon PW. Impact of mitochondrial toxicity of HIV-1 antiretroviral drugs on lipodystrophy and metabolic dysregulation. Curr Pharm Des 2010; 16: 3339-3351
4. Olivero OA, Anderson LM, Diwan BA,. et al. Transplacental effects of 3-azido-2, 3-dideoxythymidine (AZT): Tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 1997; 89: 1602-1608
5. Poirier MC, Olivero OA, Walker DM, Walker VE. Perinatal genotoxicity and carcinogenicity of antiretroviral nucleoside analog drugs. Toxicol Appl Pharmacol 2004; 199: 151-161
6. IARC. Some antiviral and antineoplastic drugs, and other pharmaceutical agents. Volume 76. World Health Organization, International Agency for Research On Cancer. Lyon; 2000
7. Borojerdi JP, Ming J, Cooch C,. et al. Centrosomal amplification and aneuploidy induced by the antiretroviral drug AZT in hamster and human cells. Mutat Res 2009; 665: 67-74
8. Benhammou V, Warszawski J, Bellec S,. et al. Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors. AIDS 2008; 22: 2165-2177
9. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1: 417-422
10. CopelandWC. Defects in mitochondrial DNA replication and human disease. Crit Rev Biochem Mol Biol 2012; 47: 64-74
11. Foster C, Lyall H. HIV and mitochondrial toxicity in children. J Antimicrob Chemother 2008; 61: 8-12
12. Poirier MC, Divi RL, Al-Harthi L,. et al. Long-term mitochondrial toxicity in HIVuninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 2003; 33: 175-183
13. Divi RL, Walker VE, Wade NA,. et al. Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to combivir. AIDS 2004; 18: 1013-1021
14. Brogly SB, Ylitalo N, Mofenson LM,. et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS 2007; 21: 929-938
15. Divi RL, Doerge DR, Twaddle NC,. et al. Metabolism and pharmacokinetics of the combination zidovudine plus lamivudine in the adult Erythrocebus patas monkey determined by liquid chromatography-tandem mass spectrometric analysis. Toxicol Appl Pharmacol 2008; 226: 206-211
16. Olivero OA, Torres LR, Gorjifard S,. et al. Perinatal exposure of patas monkeys to antiretroviral nucleoside reverse-transcriptase inhibitors induces genotoxicity persistent for up to 3 years of age. J Infect Dis 2013; 208: 244-248
17. Andre-Schmutz I, Dal-Cortivo L, Six E,. et al. Genotoxic signature in cord blood cells of newborns exposed in utero to a zidovudine-based antiretroviral combination. J Infect Dis 2013; 208: 235-243
18. Lipshultz SE, Shearer WT, Thompson B,. et al. Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute cardiovascular status of HAART therapy in HIV-exposed infants and children cohort study). J Am Coll Cardiol 2011; 57: 76-85
19. Lipshultz SE, Mas CM, Henkel JM,. et al. HAART to heart: Highly active antiretroviral therapy and the risk of cardiovascular disease inHIV-infected or exposed children and adults. Expert Rev Anti Infect Ther 2012; 10: 661-674
20. Lipshultz SE, Miller TL, Wilkinson JD,. et al. Cardiac effects in perinatally HIV-infected and HIV-exposed but uninfected children and adolescents: A view from the United States of America. J Int AIDS Soc 2013; 16: 18597
21. Wilkinson JD, Williams PL, Leister E,. et al. Cardiac biomarkers in HIV-exposed uninfected children. AIDS 2013; 27: 1099-1108
22. Crain MJ, Williams PL, Griner R,. et al. Point-of-care capillary blood lactate measurements in human immunodeficiency virus-uninfected children with in utero exposure to human immunodeficiency virus and antiretroviral medications. Pediatr Infect Dis J 2011; 30: 1069-1074
23. Kerr SJ, Puthanakit T, Vibol U,. et al. Neurodevelopmental outcomes in HIVexposed-uninfected children versus those not exposed to HIV. AIDS Care 2014; 26: 1327-1335
24. Afran L, Garcia Knight M, Nduati E,. et al. HIV-exposed uninfected children: A growing population with a vulnerable immune system?. Clin Exp Immunol 2014; 176: 11-22
25. Reikie BA, Adams RC, Leligdowicz A,. et al. Altered innate immune development in HIV-exposed uninfected infants. J Acquir Immune Defic Syndr 2014; 66: 245-255
26. Divi RL, Leonard SL, Kuo MM,. et al. Transplacentally exposed human and monkey newborn infants show similar evidence of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity. Environ Mol Mutagen 2007; 48: 201-209
27. Cote HC, Gerschenson M, Walker UA,. et al. Quality assessment of human mitochondrial DNA quantification: mitonauts, an international multicentre survey. Mitochondrion 2011; 11: 520-527
28. Gingelmaier A, Grubert TA, Kost BP,. et al. Mitochondrial toxicity in HIV type-1-exposed pregnancies in the era of highly active antiretroviral therapy. Antivir Ther 2009; 14: 331-338
29. Ross AC, Leong T, Avery A,. et al. Effects of in utero antiretroviral exposure on mitochondrial DNA levels, mitochondrial function and oxidative stress. HIV medicine 2012; 13: 98-106
30. Divi RL, Einem TL, Fletcher SL,. et al. Progressive mitochondrial compromise in brains and livers of primates exposed in utero to nucleoside reverse transcriptase inhibitors (NRTIs). Toxicol Sci 2010; 118: 191-201
31. Divi RL, Leonard SL, Kuo MM,. et al. Cardiac mitochondrial compromise in 1-yr-old Erythrocebus patas monkeys perinatally-exposed to nucleoside reverse transcriptase inhibitors. Cardiovasc Toxicol 2005; 5: 333-346